Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

Findings suggest Zilretta could potentially provide a cost-effective treatment option for patients with osteoarthritis of the knee BURLINGTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (NASDAQ: FLXN ) today announced the findings from a new health economics analysis of….


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.